JW Holdings starts to export Winuf to Mongolia

Following the first export to Mongolia, the company plans to expand its multi-nutritional liquid in Asian markets

JW Holdings multi-nutritional liquid Winuf (Courtesy of JW Holdings)
JW Holdings multi-nutritional liquid Winuf (Courtesy of JW Holdings)
Ji-Hyun Lee 1
2023-11-28 18:08:18 bluesky@hankyung.com
Bio & Pharma


South Korea's JW Holdings corporation announced on Tuesday that it started to export the multi-nutritional liquid Winuf Central 736·1085ml to Mongolia.

This is the first export of Winuf to the country in Asia. The company expects to expand the export of Winuf in the Asian market.  

Winuf is a multi-nutritional liquid developed by JW Lifescience Corporation. Since its domestic launch in 2013, it has been the leader in the multi-nutritional liquid market.

The product, which divides one container into three chambers, allows for easy mixing of four types of lipids, amino acids, glucose, and more.


JW Holdings, responsible for JW Group's global business, signed an exclusive supply contract with Asia Pharma in December 2021. In December last year, Asia Pharma got approval for the Winuf from the Mongolian Ministry of Health and began local sales this month.

Write to Ji-Hyun Lee at bluesky@hankyung.com
#JW Holdings #JW Life Science #Winnerp #multi-nutritional liquid

JW Pharma to conduct Phase 3 trials in Thailand for gout treatment

JW Pharma to conduct Phase 3 trials in Thailand for gout treatment

The headquarters of JW Pharmaceutical in Gwacheon South Korea's JW Pharmaceutical Corp. on Thursday said it received approval from Thailand's Food and Drug Administration to conduct Phase 3 clinical trials for the company's gout candidate drug Epaminurad (URC102).This is the second internationa

JW Pharma to participate in S.Korea’s new drug project

JW Pharma to participate in S.Korea’s new drug project

South Korea's JW Pharmaceutical announced on Monday that its experimental hair loss drug, JW0061, has been selected for a two-year funding program by the Korea Drug Development Fund (KDDF), the country's premier public funder of pharmaceutical research and development.JW0061, described as a gr

JW Pharma gets OK for phase 3 clinical trials of URC102 in Taiwan

JW Pharma gets OK for phase 3 clinical trials of URC102 in Taiwan

The headquarters of JW Pharmaceutical in Gwacheon South Korea's JW Pharmaceutical has won approval from Taiwan's Food and Drug Administration (TFDA) to conduct phase 3 clinical trials for its gout treatment, Epaminurad (URC102), the company said on Friday.Epaminurad, an oral uric acid transport

JW Pharma unveils S.Korea's first homegrown hybrid incubator

JW Pharma unveils S.Korea's first homegrown hybrid incubator

South Korea's JW Pharmaceutical on Wednesday released three products from its new incubator brand Hi-Mammi.The company's rollout of hybrid and high- and low-end models was its first product launch since acquiring the medical device unit of affiliate JW Bioscience in January.The Hi-Mammi incuba

JW Pharma to use zebrafish in new drug development

JW Pharma to use zebrafish in new drug development

South Korean drug developer JW Pharmaceutical has entered into a memorandum of understanding (MOU) with Zefit, a domestic non-clinical trial institute that specializes in zebrafish models, to expedite the development of new drugs, the company said on Monday. As per the agreement, JW Pharmaceut
(* comment hide *}